Axsome Therapeutics, Inc. (FRA:19X)
Germany
· Delayed Price · Currency is EUR 128.40
0.00 (0.00%)
At close: Dec 5, 2025
Axsome Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -229.53 | -287.22 | -239.24 | -187.13 | -130.4 | -102.9 | Upgrade
|
| Depreciation & Amortization | 8.86 | 7.96 | 6.83 | 4.4 | 0.08 | 0.08 | Upgrade
|
| Other Amortization | 1.85 | 2.64 | 2.57 | 1.48 | 1.08 | 0.79 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 7.16 | Upgrade
|
| Stock-Based Compensation | 93.01 | 85.22 | 62.62 | 37.73 | 20.8 | 14.76 | Upgrade
|
| Other Operating Activities | 27.75 | 29.09 | 50.52 | 3.34 | -0.1 | 1.26 | Upgrade
|
| Change in Accounts Receivable | -72.41 | -47.18 | -57.12 | -37.7 | - | - | Upgrade
|
| Change in Inventory | -8.15 | 0.74 | -8.16 | -1.33 | - | - | Upgrade
|
| Change in Accounts Payable | -10.03 | 31.32 | 2.07 | 25.46 | -0.36 | 2.56 | Upgrade
|
| Change in Other Net Operating Assets | 87.69 | 49.02 | 34.81 | 37.24 | 0.68 | -2.15 | Upgrade
|
| Operating Cash Flow | -100.95 | -128.41 | -145.08 | -116.51 | -108.23 | -78.46 | Upgrade
|
| Capital Expenditures | -0.44 | -0.27 | -0.58 | -0.7 | -0.31 | -0.05 | Upgrade
|
| Cash Acquisitions | - | - | - | -53 | - | - | Upgrade
|
| Investing Cash Flow | -0.44 | -0.27 | -0.58 | -53.7 | -0.31 | -0.05 | Upgrade
|
| Long-Term Debt Issued | - | - | 85 | 45 | - | 50 | Upgrade
|
| Long-Term Debt Repaid | - | -0.99 | - | - | - | -21.66 | Upgrade
|
| Total Debt Repaid | -263.9 | -0.99 | - | - | - | -21.66 | Upgrade
|
| Net Debt Issued (Repaid) | -3.9 | -0.99 | 85 | 45 | - | 28.34 | Upgrade
|
| Issuance of Common Stock | 124.02 | 71.46 | 271.17 | 250.01 | 11.84 | 15.18 | Upgrade
|
| Repurchase of Common Stock | -6.6 | -3.95 | -1.84 | -0.53 | -0.18 | - | Upgrade
|
| Other Financing Activities | -14.19 | -8.68 | -23.32 | -9.9 | -0.53 | -1.1 | Upgrade
|
| Financing Cash Flow | 99.32 | 57.84 | 331.01 | 284.58 | 11.13 | 42.41 | Upgrade
|
| Net Cash Flow | -2.07 | -70.84 | 185.35 | 114.37 | -97.4 | -36.09 | Upgrade
|
| Free Cash Flow | -101.39 | -128.68 | -145.66 | -117.21 | -108.53 | -78.5 | Upgrade
|
| Free Cash Flow Margin | -18.07% | -33.36% | -53.83% | -234.25% | - | - | Upgrade
|
| Free Cash Flow Per Share | -2.06 | -2.69 | -3.21 | -2.88 | -2.88 | -2.11 | Upgrade
|
| Cash Interest Paid | 16.33 | 19.69 | 16.73 | 7.69 | 4.63 | 2.1 | Upgrade
|
| Levered Free Cash Flow | -17.76 | -28.71 | -78.72 | -42.36 | -59.52 | -47.37 | Upgrade
|
| Unlevered Free Cash Flow | -14.87 | -27.25 | -77.26 | -39.26 | -57.04 | -46.55 | Upgrade
|
| Change in Working Capital | -2.9 | 33.9 | -28.39 | 23.67 | 0.32 | 0.41 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.